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T cell receptor (TCR) signaling plays an important role in early interleukin (IL)-4 production 
by naive CD4
 
 
 
 T cells. This “antigen-stimulated” early IL-4 is sufficient for in vitro Th2 
differentiation. Here, we provide evidence that early IL-4 production by naive CD4
 
 
 
 
T cells stimulated with cognate peptide requires TCR-induced early GATA-3 expression 
and IL-2 receptor signaling, both of which are controlled by the degree of activation of 
extracellular signal-regulated kinase (ERK). Stimulation of naive CD4
 
 
 
 T cells from TCR 
transgenic mice with low concentrations of peptide-induced IL-2–dependent STAT5 
phosphorylation, IL-4-independent early GATA-3 expression, and IL-4 production. 
Neutralization of IL-2 abolished early IL-4 production without affecting early GATA-3 
expression. In addition, naive CD4
 
 
 
 
 
T cells from GATA-3 conditional KO mice failed to 
produce early IL-4 in response to TCR/CD28 stimulation. Stimulation with high concentrations 
of peptide abrogated early GATA-3 expression and IL-2–dependent STAT5 phosphorylation, 
and resulted in the failure to produce early IL-4. This high concentration–mediated 
suppression of early IL-4 production was reversed by blockade of the ERK pathway. A MEK 
inhibition rescued early GATA-3 expression and responsiveness to IL-2; these cells were 
now capable of producing early IL-4 and undergoing subsequent Th2 differentiation.
 
Naive CD4
 
 
 
 T cells can differentiate into at
least two major distinct phenotypes, Th1 and
Th2 cells, which are characterized by polarized
patterns of cytokine production. Many factors
have been reported to play a role in differentia-
tion to the Th1 and Th2 phenotypes. Among
these, the set of cytokines present during the
priming period is particularly important. The
presence of IL-4 is critical for in vitro Th2 dif-
ferentiation (1, 2), whereas in vitro Th1 differ-
entiation depends heavily on IFN-
 
 
 
 and/or
IL-12 (3, 4). Recently, IL-2 has been established
as playing a major role in Th2 differentiation
(5). Mast cells (6, 7), eosinophils (8), basophils
(9–11), and NK T cells (12) have been reported
to produce IL-4; however, it is still debated
whether these cell populations serve as exoge-
nous sources of IL-4 during the priming period.
Naive CD4
 
 
 
 T cells are capable of producing
IL-4 when they are stimulated with peptide/
MHC class II complex on APCs; this endoge-
nously produced IL-4 was shown to be sufficient
for Th2 differentiation. When no polarizing
cytokines are added to a culture, strength of sig-
nal through TCR may control Th cell differenti-
ation (13). Thus, priming for IL-4–producing
cells often is observed when a low concentration
of antigen-derived peptide is used, whereas
high concentrations of peptide were reported
to induce IFN-
 
 
 
–producing cells (14). Similarly,
priming with ligands that interact with TCR
less energetically than a WT peptide, so-called
“altered peptide ligands,” often favors Th2
differentiation (15).
The basis of the “signal strength” effect on
biasing differentiation to Th1 or Th2 subset
has not been clarified, although evidence for
the involvement of NFAT (16), extracellular
signal-regulated kinase (ERK), and activated
protein-1 (AP-1) (17) has been presented. We
have reexamined the “dose effect” on priming
for Th cell differentiation using rigorously puri-
fied naive CD4
 
 
 
 T cells from TCR transgenic
mice. We show that low concentrations of
peptide induce IL-4–independent induction of
IL-4 mRNA beginning at 14–16 h after stim-
ulation. This early IL-4 mRNA expression is
associated with IL-4–independent early GATA-3
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expression and is dependent on IL-2. However, IL-2 is not
essential for early GATA-3 expression. Moreover, naive
CD4
 
 
 
 T cells from GATA-3 conditional KO mice fail to ex-
press IL-4 mRNA in response to TCR stimulation indicating
that early IL-4 transcription is GATA-3 dependent. High
concentrations of peptide inhibit early IL-4 mRNA expres-
sion by abrogating early GATA-3 induction and by blocking
IL-2R-mediated signaling, as shown by the failure of STAT5
phosphorylation, although IL-2 is produced abundantly. This
high concentration–mediated inhibition is reversed by the
blockade of ERK pathway by an inhibitor of mitogen-acti-
vated protein kinase kinase (MEK) allowing the cells to ex-
press GATA-3 and to respond to IL-2. This results in the res-
toration of early IL-4 mRNA expression and subsequent
development into high-rate IL-4–producing cells. We con-
clude that TCR-mediated control of Th2 differentiation is
dependent upon early IL-4 transcription determined by the
independent actions of GATA-3 and IL-2, and that the dose
effect reflects dose-dependent control of early transcription of
GATA-3 and high dose desensitization of the IL-2R medi-
ated by TCR-induced ERK activation.
 
RESULTS
Peptide concentration regulates priming of naive CD4
 
 
 
 
 
T cells for IL-4–producing cells
 
We isolated highly pure naive (CD44
 
low
 
CD62L
 
high
 
) CD4
 
 
 
 T
cells from 5C.C7 TCR transgenic RAG2
 
 
 
/
 
 
 
 B10.A (line
94) mice (Fig. 1 A). Splenic DCs were purified by isolating
CD11c
 
 
 
 cells followed by the removal of NK cells and NK
T cells by cell sorting (Fig. 1 A), because NK cells and NK T
cells were reported to produce large amounts of IFN-
 
 
 
 and
IL-4, respectively (12, 18), which may bias
 
 
 
T cell priming
toward Th1 or Th2 differentiation. Naive line 94 CD4
 
 
 
 T
cells and splenic DCs were co-cultured in the presence of
0.001–10 
 
 
 
M pigeon cytochrome 
 
c
 
 peptide (pPCC) without
adding any exogenous cytokines. In some experiments, we
used P13.9 cells as APCs, instead of splenic DCs. Intracellu-
lar staining for IL-4 and IFN-
 
 
 
 was performed following re-
Figure 1. Peptide concentration regulates priming of naive CD4  
T cells to develop into IL-4–producing cells. (A) Surface phenotypes of 
line 94 CD4  T cells and of splenic DCs used for experiments. In this and in 
subsequent figures, the numbers in quadrants indicate the percent of cells 
in the given quadrant. (B) Naive line 94 CD4  T cells were stimulated with 
splenic DCs and 0.001–10  M pPCC in the presence or absence of anti–IL-12 
(10  g/ml), anti–IFN-  (10  g/ml), or rat IgG1 (10  g/ml) plus rat IgG2a 
(10  g/ml) as isotype controls. Intracellular staining for IL-4 and IFN-  
was performed. (C) Unsorted or naive line 94 CD4  T cells were stimulated 
with P13.9 cells in the presence of 0.001–10  M pPCC. Intracellular staining 
for IL-4 and IFN-  was carried out after restimulation. All experiments 
were performed at least three times with consistent results. 
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call challenge with immobilized anti-CD3 plus anti-CD28
for 6 h. Stimulating naive line 94 cells with 0.001 
 
 
 
M pPCC
with splenic DCs or P13.9 cells resulted in the development
of cells that were capable of producing IL-4. When P13.9
cells were used, IL-4–producing cells also were induced with
0.01 
 
 
 
M pPCC. The frequency of IL-4 producers declined
strikingly as the concentration of pPCC was increased (Fig.
1, B and C). This decline was not reversed by the inclusion
of anti–IL-12 or anti–IFN-
 
 
 
 in the culture, which indicated
that failure of T cells primed with high concentrations of
pPCC to become IL-4 producers is not due to endogenous
IFN-
 
 
 
 production (Fig. 1 B).
5,6-carboxyfluorescein diacetate succinimidyl ester
(CFSE) dilution revealed that IL-4 was produced mainly by
cells that had undergone four or more divisions at 0.001 
 
 
 
M
when splenic DCs were used as APCs (Fig. S1, available
at http://www.jem.org/cgi/content/full/jem.20051304/
DC1), and three or more divisions at 0.001–0.01 
 
 
 
M when
P13.9 cells were used as APCs (Fig. S2, available at http://
www.jem.org/cgi/content/full/jem.20051304/DC1). The
peak number of cell divisions was five at all concentrations of
peptide tested when splenic DCs were used as APCs (Fig.
S1) and at 
 
 
 
0.01 
 
 
 
M when P13.9 cells were used as APCs
(Fig. S2). Thus, the failure of cells to divide a sufficient num-
ber of times cannot account for high concentrations of pep-
tide not leading to the production of IL-4.
IFN-
 
 
 
 was produced by T cells cultured with splenic
DCs at low and high concentrations of peptide; anti–IL-12
did not block the development of IFN-
 
 
 
–producing cells,
but anti–IFN-
 
 
 
 did (Fig. 1 B). When P13.9 cells were used,
few, if any, IFN-
 
 
 
–producing cells appeared, even without
neutralization of IFN-
 
 
 
 or IL-12 (Fig. 1 C). Thus, splenic
DCs and P13.9 cells differ in their capacity to induce naive
CD4
 
 
 
 T cells to develop into IFN-
 
 
 
 producers, even in the
absence of IL-12. Because splenic DCs were shown recently
not to produce IFN-
 
 
 
 (18), this suggests that the APCs differ
in their intrinsic capacity to stimulate naive CD4
 
 
 
 T cells to
produce “early” IFN-
 
 
 
. P13.9 cells did stimulate priming for
IFN-
 
 
 
 production if small numbers of CD44
 
high
 
 (memory)
line 94 CD4
 
 
 
 T cells were present (Fig. 1 C). The latter cells
presumably served as a source of “early” IFN-
 
 
 
 upon stimu-
lation (unpublished data).
Figure 2. Peptide concentration-dependent inhibition of early IL-4 
and GATA-3 mRNA expression. (A) Naive line 94 CD4  T cells were 
stimulated with P13.9 cells in the presence of 0.001–10  M of pPCC. Total 
RNA was harvested at indicated time points and relative mRNA levels for 
IL-4, GATA-3, IL-2, and IFN-  were analyzed by real-time PCR. (B) Naive 
line 94 CD4  T cells were stimulated with 0.01 or 10  M pPCC on P13.9 
cells. Cells were harvested 20 h after stimulation, and CD4 and GATA-3 
were visualized by confocal microscopy. (C) Naive line 94 CD4  T cells 
were stimulated with 0.01  M pPCC on P13.9 cells in the presence or 
absence of anti–IL-4 (10  g/ml), anti–IL-2 (10  g/ml) plus anti-CD25 
(10  g/ml), or rat IgG1 (10  g/ml) plus rat IgG2a (10  g/ml) as isotype 
controls. Total RNA was harvested at indicated time points, and relative 
mRNA levels for IL-4 and GATA-3 were analyzed by a real-time PCR. 
(D) CFSE-labeled naive line 94 CD4  T cells were stimulated as described 
in C. Intracellular IL-4 and IFN-  were stained after restimulation. All 
experiments were carried out at least three times with consistent results. 
THE MECHANISM OF INHIBITING IL-4 PRODUCTION BY ERK | Yamane et al.
 
796
 
High peptide concentration-induced activation is inhibitory 
for TCR-induced early IL-4 mRNA expression
 
In subsequent experiments, P13.9 cells were used as APCs,
because the antigen concentration effects held when splenic
DCs or P13.9 cells were used to present pPCC. We examined
the early expression of IL-4 mRNA in naive line 94 CD4
 
 
 
T cells primed with various concentrations of pPCC. IL-4
mRNA was first detectable at 14 h in cells that were stimu-
lated with 0.01 
 
 
 
M pPCC, and increased in level of expres-
sion by 20–24 h (Fig. 2 A). Increasing the concentration of
pPCC to 0.1 
 
 
 
M diminished the amount of IL-4 mRNA by
 
 
 
10-fold, and IL-4 mRNA was barely detectable when 10
 
 
 
M pPCC was used for priming. This early IL-4 mRNA ex-
pression was independent of IL-4 as shown by the failure of
anti–IL-4 to diminish the level of IL-4 mRNA in cells that
were stimulated for 24 h with 0.01 
 
 
 
M pPCC (Fig. 2 C).
The induction of GATA-3 mRNA followed a similar
dose-dependent pattern to that of IL-4 mRNA (Fig. 2 A).
GATA-3 mRNA first exceeded the level found in naive line
94 CD4
 
 
 
 T cells at 14 h of stimulation with 0.01 
 
 
 
M
pPCC. GATA-3 mRNA levels increased at 24 h after stim-
ulation. Cells stimulated with 
 
 
 
1 
 
 
 
M pPCC failed to ex-
press GATA-3 mRNA. Analysis of GATA-3 protein by
confocal microscopy indicated that it was expressed in the
nucleus of line 94 CD4
 
 
 
 T cells stimulated for 20 h with
0.01 
 
 
 
M, but not 10 
 
 
 
M, pPCC (Fig. 2 B). The 24-h ex-
pression of GATA-3 mRNA and protein induction was not
inhibited by anti–IL-4 (Fig. 2 C; not depicted).
IFN-
 
 
 
 mRNA levels were extremely low throughout
the first 24 h of culture; there was no significant difference in
IFN-
 
 
 
 mRNA expression among cell populations that were
stimulated with different concentrations of pPCC (Fig. 2 A).
IL-2 mRNA was induced by 6 h of culture and showed an
entirely different concentration dependence from that of
IL-4 mRNA (Fig. 2 A). IL-2 mRNA was maximal at 1 and
10 
 
 
 
M and 
 
 
 
10-fold lower at 0.01 
 
 
 
M pPCC.
 
Expression of IL-4 and GATA-3 after 24 h is IL-4 dependent
 
Culturing naive line 94 CD4
 
 
 
 T cells with 0.01 
 
 
 
M peptide in
the presence of anti–IL-4 did not affect the amount of IL-4 or
GATA-3 mRNA at 24 h. However, the presence of anti–IL-4
prevented the increase in IL-4 and GATA-3 mRNA levels that
were observed at 48 and 72 h when “early” IL-4 was not neu-
tralized (Fig. 2 C). Furthermore, if IL-4 was added from the
outset of the culture, the amount of IL-4 and GATA-3 mRNA
that was expressed by the cells at all time points throughout
72 h was increased further (unpublished data). These results in-
dicate that, in cells cultured under neutral conditions, the early
“IL-4–independent” IL-4 that is produced is essential for the
continued production of IL-4 and the continued expression of
GATA-3 by these cells. Anti–IL-4 reduced the frequency of
cells producing IL-4 in response to challenge with pPCC (0.01
 
 
 
M) at 72 h from 35.6 to 4.8% (Fig. 2 D). This implied that
the further induction of IL-4 by endogenous “early” IL-4 is es-
sential for the differentiation of naive CD4
 
 
 
 T cells into cells
that are capable of secreting large amounts of IL-4.
 
IL-2 is essential for early IL-4, but not GATA-3, induction
 
Adding anti–IL-2 and anti-CD25 to cells that were cultured
under neutral conditions completely inhibited the early (24 h)
appearance of IL-4 mRNA but had no inhibitory effect on
early GATA-3 mRNA (Fig. 2 C) or protein expression (not
depicted). At 48 h, IL-4 mRNA still was not observed and
GATA-3 mRNA levels failed to increase (Fig. 2 C), presum-
ably because of the lack of IL-4, which is essential for the
further increase of GATA-3 mRNA (19). The effect of neu-
tralizing IL-2 on early IL-4 mRNA expression could not be
accounted for by its effects on cell growth, because there was
no cell division during the first 24 h of culture—as measured by
CFSE dilution—and cell yield at 24 h was not affected by the
addition of anti–IL-2 and anti-CD25 (unpublished data). To-
gether, these results imply that early IL-4 production depends
on the induction of GATA-3 and on an IL-2–mediated event.
 
GATA-3–deficient naive CD4
 
 
 
 T cells fail to produce IL-4 in 
response to in vitro challenge
 
Although GATA-3 was demonstrated to play a critical role in
Th2 differentiation (19–22), it has remained unclear whether
GATA-3 is involved in IL-4–independent early IL-4 produc-
Figure 3. Naive CD4  T cells lacking Gata3 gene fail to produce early 
IL-4. (A) CD44 and CD62L expression by unsorted and FACS-sorted CD4  
T cells from Gata3f/f mice and Gata3f/fCD4-Cre mice. (B) Naive CD4  T cells 
from Gata3f/f mice and Gata3f/fCD4-Cre mice were stimulated with immo-
bilized anti-CD3 (1  g/ml) and anti-CD28 (3  g/ml) in the presence or 
absence of 10  g/ml anti–IL-4. Cells were harvested 24 h after stimulation 
and relative mRNA levels for IL-4 and IL-2 were measured by real-time 
PCR. *not detectable, N.D., not done. The experiment was performed twice 
with consistent results.JEM VOL. 202, September 19, 2005 797
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tion. To address this question, we crossed mice that were ho-
mozygous for a “floxed” Gata3 gene (22) onto CD4-Cre
transgenic mice (Gata3f/fCD4-Cre mice) (23), so that the
Gata3 gene could be deleted in peripheral T cells. These
mice possess few CD4  T cells (not depicted), and most of
those that are present exhibit a memory or effector/memory
phenotype (Fig. 3 A). We purified CD44lowCD62LhighCD4 
T cells from these mice and from mice that were homozy-
gous for the floxed gene without CD4-Cre (Gata3f/f) (Fig. 3
A). Such “naive” cells derived from Gata3f/fCD4-Cre mice
failed to express IL-4 mRNA 24 h after stimulation, whereas
those derived from Gata3f/f mice expressed considerable
amounts of IL-4 mRNA in response to immobilized anti-
CD3 and anti-CD28; this IL-4 mRNA expression was not
inhibited by anti–IL-4 (Fig. 3 B). Thus, deletion of GATA-3
prevented early expression of IL-4 mRNA in response to
TCR-mediated stimulation. Cells from Gata3f/fCD4-Cre
mice were equivalent to those from Gata3f/f mice in their ca-
pacity to induce IL-2 mRNA in response to anti-CD3 and
anti-CD28 (Fig. 3 B), which indicated that loss of GATA-3
does not influence the degree of T cell activation.
High concentrations of pPCC inhibit STAT5 phosphorylation 
in cells cultured for 24 h
High concentrations of peptide block early GATA-3 expres-
sion and inhibit the responsiveness of the cells to IL-2. Thus,
when naive line 94 CD4  T cells were cultured for 24 h with
P13.9 cells that had been preloaded with 0.01  M pPCC, the
CD25  cells that arose as a result of stimulation could be
stained with an anti–phospho-STAT5 antibody (Fig. 4). This
staining did not occur if the cells had been incubated in anti–
IL-2 and anti-CD25 during the culture period, and was not
observed in the CD25  cells; this indicated that staining for
phospho-STAT5 is specific for IL-2–mediated event. Neu-
tralizing IL-2 and blocking CD25 did not diminish the fre-
quency of CD25  cells at 24 h substantially. Although high
concentrations of peptide caused the expression of  10-fold
more IL-2 mRNA than did low concentrations (Fig. 2 A),
naive CD4  T cells stimulated with high concentrations of
peptide failed to show phospho-STAT5 among their CD25 
cells; this implied that high concentrations of peptide “desen-
sitized” the IL-2 receptor. Thus, the failure of naive CD4  T
cells that were stimulated with high concentrations of peptide
to produce early IL-4 could be attributed to the failure to in-
duce GATA-3 and to transduce IL-2R–mediated signaling.
A MEK inhibitor allows naive CD4  T cells that 
are stimulated with high concentrations of 
peptide to produce early IL-4
To examine whether mitogen-activated protein kinase
(MAPK) pathways mediate high peptide concentration-
dependent suppression of IL-4–independent early IL-4 pro-
duction, naive line 94 CD4  T cells were pretreated with
specific inhibitors of p38 MAPK, c-Jun N-terminal kinase
(JNK), or MEK, the upstream regulator of ERK, and stimu-
lated with 10  M pPCC. Inhibiting the p38 MAPK or JNK
pathways did not allow such “high-dose” cells to express
IL-4 mRNA at 24 h (Fig. 5 A), or to develop into IL-4-pro-
ducers at 72 h (Fig. 5 B). However, a MEK inhibitor (U
0126) caused a dose-dependent increase in IL-4 mRNA ex-
pression at 24 h (Fig. 5 A), and resulted in priming for high-
rate IL-4–producing cells (Fig. 5 B).
U 0126 pretreatment also restored early GATA-3 mRNA
expression in a dose-dependent manner, whereas neither the
p38 inhibitor nor the JNK inhibitor induced the expression
of GATA-3 mRNA (Fig. 5 A). Restoration of GATA-3
protein expression by U 0126 was confirmed by confocal
microscopic analysis (Fig. 5 C).
Moreover, blockade of the ERK pathway allowed cells
that were stimulated with high concentrations of peptide to
respond to IL-2. Thus, naive line 94 CD4  T cells without
U 0126 pretreatment failed to show IL-2–driven STAT5
phosphorylation at 24 h, although they did express phospho-
STAT5 at 48 h (Fig. 5 D). By contrast, in cells that were
pretreated with U 0126, a small, but significant, degree of
IL-2–driven STAT5 phosphorylation was observed at 24 h;
phosphorylation was enhanced further at 48 h (Fig. 5 D).
These results indicate that ERK activation, as a result of
stimulation with high concentrations of peptide, suppresses
early GATA-3 mRNA induction and IL-2R–mediated sig-
naling, which jointly result in the failure of “high-dose” cells
to produce early IL-4. Stimulation of line 94 CD4  T cells
with 10  M pPCC induced striking phosphorylation of
ERK, as shown by flow cytometric analysis with an anti–
phospho-ERK antibody (Fig. 6; open line graphs). By con-
trast, little or no ERK phosphorylation was detected in cells
that were stimulated with 0.01  M pPCC at any time from
2 min to 2 h after stimulation (Fig. 6; open line graphs). Pre-
treatment of line 94 CD4  T cells with U 0126 blocked
TCR-induced ERK phosphorylation in response to low and
high concentrations of pPCC (Fig. 6; shaded line graphs).
Figure 4 Stimulation with high concentrations of peptide renders 
T cells unresponsive to IL-2. Naive line 94 CD4  T cells were stimulated 
with 0.01 or 10  M pPCC on P13.9 cells in the presence or absence of 
anti–IL-2 (10  g/ml) and anti-CD25 (10  g/ml). Cells were harvested 24 h 
after stimulation; fixed; permeabilized; and then stained for CD4, CD25, 
and phospho-STAT5. The number in the upper right quadrant indicates the 
proportion of phospho-STAT5  cells within CD25  cells that arose as a 
result of activation. The experiment was performed three times with 
consistent results.THE MECHANISM OF INHIBITING IL-4 PRODUCTION BY ERK | Yamane et al. 798
Blockade of the ERK pathway inhibits priming for 
IL-4–producing cells at low concentrations of peptide
We examined how blockade of the ERK pathway influ-
enced the priming of naive CD4  T cells with different con-
centrations of peptide. Thus, CFSE-labeled naive line 94
CD4  T cells that were pretreated with U 0126 were cul-
tured for 72 h with P13.9 cells that had been loaded with
0.001–10  M pPCC. U 0126 pretreatment strikingly en-
hanced the frequency of IL-4–producing cells at 0.1  M or
more pPCC, but dramatically suppressed the frequency of
IL-4 producers at 0.01  M or less pPCC, with only a rela-
tively modest effect on cell division (Fig. 7 A).
To examine how blocking the ERK pathway exerted
different effects on priming for IL-4–producing cells when
low and high concentrations of peptide were used, we car-
ried out a kinetic analysis of IL-4 and GATA-3 mRNA by
real-time PCR in cells that were pretreated with U 0126 and
stimulated with 0.01 or 10  M pPCC. U 0126 pretreatment
had no inhibitory effect on IL-4 or GATA-3 mRNA ex-
pression in cells that were stimulated with 0.01  M pPCC at
24 h, but it strikingly diminished expression at 48 and 72 h
(Fig. 7 B). In contrast, U 0126 pretreatment allowed IL-4–
independent expression of IL-4 and GATA-3 mRNA in
cells that were stimulated with 10  M pPCC at 24 h; this
resulted in a further enhancement of both mRNAs at 48 and
72 h that largely was IL-4 dependent (Fig. 7 B).
c-Maf was shown to play an important role in IL-4 pro-
duction; its expression is induced by TCR stimulation (24,
25). Therefore, it was possible that blocking the ERK
pathway might down-regulate TCR-induced c-Maf ex-
pression at low peptide concentration, causing the failure to
sustain IL-4 mRNA expression in the late phase of activa-
tion. However, we did not observe any decrease in c-Maf
mRNA expression in cells that were pretreated with U
0126 and stimulated with 0.01  M pPCC (Fig. 7 B).
Moreover, the level of c-Maf mRNA expression in cells
that were stimulated with 10  M pPCC was higher than
that in cells with 0.01  M pPCC (Fig. 7 B). Thus, it is un-
likely that c-Maf is involved in TCR-induced early IL-4
production or that inhibition of c-Maf accounts for U
0126-mediated diminution in late IL-4 production at low
peptide concentration.
Exogenous IL-2 rescues U 0126-mediated suppression of 
Th2 priming at low peptide concentration
The diminished priming for high-rate IL-4–producing cells at
low peptide concentration seemed to be accounted for by the
diminution in IL-2 production by cells that were treated with
the MEK inhibitor. This occurred at high and low peptide
concentrations; however, the “inhibited” amounts of IL-2
mRNA at high peptide concentration still exceeded the “un-
inhibited” amounts of IL-2 mRNA in cells that were stimu-
lated with 0.01  M pPCC (Fig. 7 A). To determine whether
U 0126-mediated suppression of IL-4 production in “low-
dose” stimulated cells was due to diminution in IL-2 produc-
Figure 5. Activation of the ERK pathway is responsible for high 
peptide concentration–mediated suppression of IL-4 production. 
(A) Naive line 94 CD4  T cells that were pretreated with different concen-
trations of U 0126, SB 203580, or SP 600125 were stimulated with P13.9 
cells that had been preloaded with 10  M pPCC. Cells were harvested 24 h 
after stimulation, and the relative mRNA levels for IL-4 and GATA-3 were 
measured by real-time PCR. (B) Naive line 94 CD4  T cells were stimulated 
as described in A. Intracellular staining for IL-4 and IFN-  was carried
out after restimulation. (C) Naive line 94 CD4  T cells were pretreated with 
U 0126 (3  M) or DMSO and stimulated with P13.9 cells that were preloaded 
with 10  M pPCC. Cells were harvested 20 h after stimulation, and CD4 
and GATA-3 were visualized by confocal microscopy. (D) Naive line 94 
CD4  T cells were stimulated as in (C). Cells were harvested 24 and 48 h 
after stimulation; fixed; permeabilized; and then stained for CD4, CD25, 
and phospho-STAT5. The number in the upper right quadrant indicates the 
proportion of phospho-STAT5  cells within CD25  cells that arose as a 
result of activation. Quadrant location was determined based on the dot 
plot analysis for the cells that were stimulated in the presence of anti–IL-2 
(10  g/ml) and anti-CD25 (10  g/ml). All experiments were carried out at 
least three times with consistent results.
Figure 6 Intense phosphorylation of ERK induced by high concen-
trations of peptide. Line 94 CD4  T cells were pretreated with U 0126 
(3  M) or DMSO and stimulated with P13.9 cells that were preloaded with 
0.01 or 10  M pPCC. Cells were fixed at indicated time points, and intra-
cellular staining for phospho-ERK was performed. The levels of phospho-
ERK in U 0126- and DMSO-pretreated cells are shown in shaded and open 
line graphs, respectively. The experiment was carried out three times with 
consistent results.JEM VOL. 202, September 19, 2005 799
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tion, we supplemented these cultures with different concen-
trations of IL-2 at 24 h of stimulation. Addition of 100 U/ml
of IL-2 at 24 h restored IL-4 and GATA mRNAs at 48 and
72 h. This restoration was IL-4 dependent, which implied
that IL-2 addition allowed endogenous IL-4 production,
which in turn, was essential to up-regulate IL-4 and GATA-3
mRNA (Fig. 8 A). Addition of IL-2 at 24 h also restored
priming for high-rate IL-4–producing cells that were pre-
treated with U 0126 and stimulated with 0.01  M peptide.
30 units of IL-2 caused partial restoration, whereas 100 units
fully restored priming for IL-4–producing capacity. IL-2–
mediated restoration of priming for high-rate IL-4–produc-
ing cells was blocked completely by the inclusion of anti–
IL-4 (Fig. 8 B).
Taken together, these data suggest that decreased amounts
of IL-2, which results from the inhibition of the ERK path-
way, is sufficient to allow the IL-4–independent “early” IL-4
production at low peptide concentration, but is not sufficient
to sustain IL-4–dependent “late” IL-4 production.
MEK inhibition does not restore IL-4 production simply by 
lowering global T cell activation
Lck is activated in response to the ligation of TCR with an-
tigen peptide–MHC class II complex, and plays an important
role in the signal transduction through TCR. It was shown
that agonistic peptide-induced activated ERK phosphory-
lates Ser59 of Lck and prevents it from inactivation by the
Figure 7. U 0126 allows IL-4 priming in response to high concen-
trations of pPCC but blocks such priming in response to low concen-
trations. (A) CFSE-labeled naive line 94 CD4  T cells were pretreated with 
U 0126 (3  M) or DMSO, and stimulated with P13.9 cells that were preloaded 
with 0.001–10  M pPCC. Intracellular IL-4 and IFN-  were stained after 
restimulation. (B) U 0126 (3  M)- or DMSO-pretreated naive line 94 CD4  
T cells were stimulated with P13.9 cells that were preloaded with 0.01 or 
10  M pPCC in the presence or absence of 10  g/ml anti–IL-4. Total RNA 
was isolated at indicated time points, and relative mRNA levels for IL-4, 
GATA-3, IL-2, and c-Maf were analyzed by real-time PCR. All experiments 
were carried out three times with consistent results.
Figure 8. Exogenous IL-2 rescues U 0126-mediated suppression of 
Th2 priming at low peptide concentration. (A) U 0126 (3  M)- or 
DMSO-pretreated naive line 94 CD4  T cells were stimulated with P13.9 
cells that were preloaded with 0.01  M pPCC. At 24 h of stimulation 
(indicated by arrows), 100 U/ml rhIL-2 with or without 10  g/ml anti–IL-4 
were added to the cultures. Cells were harvested at indicated time points, 
and relative mRNA levels for IL-4 and GATA-3 were analyzed by real-time 
PCR. (B) Naive line 94 CD4  T cells were stimulated as described in (A). Differ-
ent concentrations of rhIL-2 with or without 10  g/ml anti–IL-4 or rat 
IgG1 were added to the culture at 24 h. Intracellular IL-4 and IFN-  were 
stained following restimulation. The frequency of IL-4–producing cells is 
shown. Both experiments were repeated three times with similar results.THE MECHANISM OF INHIBITING IL-4 PRODUCTION BY ERK | Yamane et al. 800
SHP-1 phosphatase; this “protected” Lck is detectable as a
59-kD protein on SDS-PAGE (26). It is possible that block-
ade of the ERK pathway by a MEK inhibitor simply de-
creases the level of T cell activation by diminishing Lck ac-
tivity, and allows naive CD4  T cells that are stimulated
with high concentrations of peptide to express early IL-4
mRNA. To determine whether the MEK inhibitor exerted
its effect by simply diminishing the degree of T cell activa-
tion in response to 10  M pPCC, we compared the relative
amount of p59lck in cells that were stimulated with various
concentrations of pPCC with that in cells that were pre-
treated with U 0126 and stimulated with 10  M pPCC (Fig.
9 A). The relative amount of p59lck increased in a peptide
concentration-dependent manner, and reached a plateau at 1
 M pPCC. U 0126 diminished the amount of p59lck in cells
that were stimulated with 10  M pPCC to an amount that
was comparable to that induced by 0.1  M pPCC. How-
ever, there were substantially greater amounts of p59lck in U
0126-pretreated cells that were stimulated with 10  M
pPCC compared with cells that were stimulated with 0.01
 M pPCC in the absence of inhibitor. Because the levels
of IL-4 and GATA-3 mRNA in U 0126-pretreated cells
that were stimulated with 10  M pPCC were significantly
higher than those in DMSO-pretreated cells that were stim-
ulated with 0.1  M pPCC and were comparable to those in
cells that were stimulated with 0.01  M pPCC (Fig. 9 B), it
is unlikely that the effects of the MEK inhibitor can be as-
cribed to a global inhibition of T cell activation.
DISCUSSION
In the present report, we provide evidence that peptide con-
centration regulates the level of IL-4–independent early
GATA-3 expression and the degree of responsiveness to IL-2,
both of which are indispensable for TCR-induced, IL-4–
independent early IL-4 production by naive CD4  T cells.
Thus, low concentrations of peptide allow naive CD4  T
cells to express early GATA-3 and to respond to IL-2.
Therefore, these cells are capable of producing early IL-4
and undergoing subsequent differentiation into high-rate IL-
4–producing (Th2) cells. By contrast, stimulation with high
concentrations of peptide abrogates early GATA-3 expres-
sion and the sensitivity to IL-2, and results in the failure to
produce early IL-4. The preferential capacity of low peptide
concentrations to induce Th2 responses also was observed by
other investigators who used naive CD4  T cells from dif-
ferent TCR transgenic mice (14, 27, 28). We also provide
evidence that the degree of ERK activation accounts for
peptide concentration–mediated early IL-4 transcription in
naive CD4  T cells.
The requirement of GATA-3 for early IL-4 transcription
is based on the evidence that naive (CD44lowCD62Lhigh)
CD4  T cells purified from spleen and lymph nodes of
Gata3f/fCD4-Cre mice failed to induce early IL-4 mRNA
when stimulated with immobilized anti-CD3 and anti-
CD28, whereas such T cells from Gata3f/f mice expressed
considerable amounts of early “IL-4–independent” IL-4
mRNA. Moreover, there is much indirect evidence that
early GATA-3 expression is required for low concentration–
mediated induction of IL-4. Thus, the dose response curve of
early GATA-3 and early IL-4 mRNA expression were the
same, and GATA-3 mRNA appeared slightly earlier than did
IL-4 mRNA (unpublished data). Although GATA-3 has
been reported to play an important role in Th2 differentia-
tion (19–22), our current work is the first to demonstrate
clearly that GATA-3 is responsible for TCR-induced, IL-4–
independent early IL-4 production by naive CD4  T cells.
We have not clarified the mechanism by which TCR-
mediated signaling induces early GATA-3 expression. Das et
al. (29) reported that CD4  T cells from NF- B p50-defi-
cient mice failed to express GATA-3 in the nucleus 96 h af-
ter stimulation with anti-CD3 and anti-CD28, and that
these cells are impaired markedly in Th2 polarization. They
also showed that CD4  T cells that were pretreated with an
inhibitor of NF- B p50 did not express GATA-3 in the nu-
cleus at 96 h. However, it remains unclear whether early
GATA-3 induction is dependent on NF- B p50. Previous
reports have demonstrated that TCR-induced NF- B acti-
vation is down-stream of protein kinase C   activation (30),
and that the degree of protein kinase C   activation is di-
Figure 9. Diminution in TCR-induced Lck activation by blocking 
the ERK pathway does not account for the restoration of early IL-4 
mRNA expression at high peptide concentration. (A) Whole cell lysates 
from DMSO-treated naive line 94 CD4  T cells that had been stimulated 
with various concentrations of pPCC on P13.9 cells, or those that were 
pretreated with 3  M U 0126 and stimulated with 10  M pPCC, were 
analyzed for Lck by Western blot. Comparable levels of ZAP70 indicate the 
equal loading of each sample. (B) U 0126 (3  M)- or DMSO-pretreated 
naive line 94 CD4  T cells were stimulated with 0.01–10  M pPCC on 
P13.9 cells. Total RNA was isolated 24 h after stimulation, and relative 
mRNA levels for IL-4 and GATA-3 were analyzed by real-time PCR. Both 
experiments were carried out three times with consistent results.JEM VOL. 202, September 19, 2005 801
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rectly dependent on the strength of TCR signaling (31).
However, given the fact that early GATA-3 expression was
suppressed in a peptide concentration–dependent manner,
the degree of NF- B activation may not account for TCR-
induced early GATA-3 expression.
We showed in the present report that blockade of the
ERK pathway allowed naive CD4  T cells that were stimu-
lated with high concentrations of peptide to induce GATA-3
mRNA and to express its protein in the nucleus. Komine
et al. (32) reported that retroviral infection with Runx1
cDNA dramatically diminished the frequency of IL-4–pro-
ducing cells by inhibiting GATA-3 mRNA expression un-
der neutral and Th2-skewing conditions. This raised the
possibility that the peptide concentration effect might be
mediated by preferential induction of Runx1 at high pep-
tide concentration. However, our real-time PCR analysis
showed no significant difference in Runx1 mRNA levels
between cells that were stimulated with low and high con-
centrations of peptide at 12–24 h of stimulation (unpub-
lished data). Moreover, U 0126 pretreatment did not alter
the levels of Runx1 mRNA expression at high peptide con-
centration. Thus, it is unlikely that Runx1 is responsible for
high peptide concentration–mediated suppression of early
GATA-3 expression.
Jorritsma et al. (17) showed that treatment of naive AND
TCR transgenic CD4  T cells with a MEK inhibitor
(PD98059) during priming with relatively high concentra-
tions (5  g/ml) of moth cytochrome c peptide resulted in an
increased ratio of nuclear JunB homodimers to JunB/c-Fos
heterodimers that was capable of binding to the IL-4 pro-
moter upon recall challenge with moth cytochrome c pep-
tide. Therefore, they concluded that robust ERK activation
inhibits IL-4 transcription by altering the pattern of distinct
AP-1 complexes. However, we observed that 10  M pPCC
induced significantly higher nuclear JunB expression than
did 0.01  M pPCC at 12 to 24 h of priming, and that pre-
treatment with U 0126 did not alter the pattern of JunB ex-
pression (unpublished data). Moreover, 0.01 and 10  M
pPCC induced comparable levels of nuclear c-Fos expres-
sion, and pretreatment with U 0126 did not alter the pattern
of c-Fos expression at low and high pPCC concentrations
(unpublished data). Therefore, although it is possible that
cells that have completed their differentiation to Th1 or Th2
phenotype have different AP-1 complexes that are capable of
binding to the IL-4-promoter, it is unlikely that the forma-
tion of such different complexes is responsible for the pep-
tide concentration–dependent early IL-4 production.
LeGros et al. (1) originally demonstrated that IL-4 and
IL-2 are required for priming of CD4  T cells to develop
into IL-4–producing cells; however, the precise role of IL-2
in Th2 priming was not clarified. Recently, Cote-Sierra et
al. (5) showed that IL-2 mediates its effect by stabilizing the
accessibility of the Il4 gene after 48 h of priming. In the
present report, we found that when naive line 94 CD4 
T cells were primed with 0.01  M pPCC, induction of
early IL-4 mRNA expression required IL-2, whereas early
GATA-3 mRNA expression was independent of IL-2. We
also observed that naive CD4  T cells from IL-2 /  5C.C7
TCR transgenic RAG2 /  mice failed to express “24-h”
IL-4 mRNA in response to 0.01  M pPCC, and that addi-
tion of exogenous IL-2 restored IL-4 mRNA expression. By
contrast, IL-2 /  cells expressed levels of GATA-3 mRNA
that were comparable to WT cells; addition of exogenous
IL-2 did not enhance its expression (Fig. S3, available at
http://www.jem.org/cgi/content/full/jem.20051304/DC1).
Although the importance of STAT5, especially STAT5a, in
Th2 differentiation has been reported (33, 34), it remains to
be elucidated whether IL-2–driven STAT5 activation is in-
volved in early IL-4 production.
In conclusion, peptide concentration–mediated strength
of TCR signaling regulates early IL-4 production by naive
CD4  T cells by controlling the levels of ERK activation
which, in turn, influence early GATA-3 expression and re-
sponsiveness to IL-2. Weak and transient ERK activation
that is induced by low concentrations of peptide allows naive
CD4  T cells to express early GATA-3 and to respond to
endogenous IL-2, both of which are required for early IL-4
production. This endogenously produced early IL-4 is re-
quired for priming of CD4  T cells to develop into high-
rate IL-4–producing (Th2) cells. By contrast, intense and
sustained ERK activation that is induced by high concentra-
tions of peptide inhibits early GATA-3 expression and tran-
siently desensitizes the IL-2R; this results in the failure of na-
ive CD4  T cells to produce early IL-4 and to undergo
subsequent Th2 differentiation.
Biologically, these results imply that low concentration
challenge of individuals without overt activation of Toll-like
receptors would lead to preferential priming of naive CD4 
T cells to develop into a Th2 phenotype, and thus, predis-
pose to allergic inflammatory response. Bottomly and col-
leagues argued that low concentrations of LPS may be
required to allow mice to develop an antigen-stimulated air-
way hypersensitivity response in vivo (35, 36). Addition of
LPS (10 ng/ml) did not alter the overall antigen concentra-
tion effects described here (unpublished data). This suggests
that peptide concentration/strength of TCR signaling may
be a central element in determining in vivo priming for Th2
responses, and thus, bias toward allergic inflammation.
MATERIALS AND METHODS
Mice. RAG2 /  B10.A mice transgenic for a 5C.C7 TCR specific for
pPCC on I-Ek (line 94 mice), IL-2 /  5C.C7 TCR transgenic RAG2 / 
B10.A mice (line 110 mice), and B10.A mice were obtained from Taconic.
Gata3f/f mice generated in our lab (22) were crossed onto CD4-Cre trans-
genic mice on a C57BL/6 background (23). All mice were bred and main-
tained under specific pathogen-free conditions in the National Institute of
Allergy and Infectious Diseases Animal Facility and used at 8–12 wk of age.
Culture media. RPMI 1640 was purchased from Biosource and supple-
mented with 10% FCS, 2-ME, glutamine, penicillin, streptomycin, and so-
dium pyruvate (referred to as cRPMI).
Reagents. FITC-anti-CD3, -CD8, -CD11b, -CD16/32, -CD24, -CD25,
-B220, -NK1.1, -DX5, -Ly-6C/6G, -I-Ak, -I-Ab; AlexaFluor 488–anti-THE MECHANISM OF INHIBITING IL-4 PRODUCTION BY ERK | Yamane et al. 802
CD4; PE–anti-CD62L, –IL-4, –goat-anti–mouse Ig, -streptavidin; Cy-
Chrome-anti-CD44, -CD4; APC–anti-CD4, –IFN- ; biotinylated anti-
CD11c; purified anti–phospho-STAT5 (clone 47), -ZAP70 (clone 29); neu-
tralizing anti–IL-2; blocking anti-CD25; rat IgG1; and rat IgG2a for isotype
controls were purchased from BD Biosciences. Anti–IL-4, anti–IL-12, anti–
IFN- , anti-CD3, and anti-CD28 were purified from ascites by Harlen.
Anti–phospho-ERK mAb (E10) was purchased from Cell Signaling Tech-
nology. Mitomycin C, SB 203580, and SP 600125 were purchased from Cal-
biochem. Anti–GATA-3 mAb (HG3-31) was purchased from Santa Cruz
Biotechnology, Inc. CFSE  and AlexaFluor 647 donkey-anti–mouse IgG
were purchased from Invitrogen. U 0126 and DAPI were purchased from
Promega and Sigma-Aldrich, respectively. pPCC (residues 88-104; KAERA-
DLIAYLKQATAK) was synthesized by American Peptide Company.
Isolation of naive CD4  T cells and splenic DCs. CD4  T cells were
isolated from lymph nodes of line 94 mice or line 110 mice by negative se-
lection using FITC-conjugated mAbs to CD8, B220, I-Ak, CD16/32,
NK1.1, and CD24, followed by incubating with anti-FITC Microbeads
(Miltenyi Biotec) and passing through a MACS LS column (Miltenyi Bio-
tec). Isolated cells were stained with PE–anti-CD62L and CyChrome anti-
CD44, and then CD44lowCD62Lhigh CD4  T cells were sorted by FACS
Vantage III SE (Becton Dickinson) and used as naive CD4  T cells. In
some experiments, naive CD4  T cells were labeled with 1.25  M CFSE
before use.
When we used Gata3f/fCD4-Cre mice and Gata3f/f mice, CD4  T cells
were isolated from spleen and lymph nodes by passing through a Mouse T
Cell Enrichment Column (R&D Systems), followed by negative selection as
described above, except FITC-anti-I-Ab was used instead of FITC-anti-I-
Ak, and FITC–anti-DX5, -CD11b and -Ly-6C/6G were added. Isolated
cells were stained with PE–anti-CD62L, Cy-Chrome–anti-CD44, and
APC–anti-CD4. CD4 CD44lowCD62Lhigh cells were sorted by FACS Van-
tage III SE (Becton Dickinson) and used as naive CD4  T cells.
DCs were isolated as follows. Spleens of B10.A mice were treated with
Liberase Brendzyme 2 and DNase I (Roche Applied Science), and CD11c 
cells were isolated by positive selection using anti-CD11c (N418) Micro-
beads (Miltenyi Biotec) and a MACS LS column. Isolated cells were stained
with biotinylated anti-CD11c (HL3) followed by PE-streptavidin and
FITC–anti-DX5, –anti-NK1.1, and –anti-CD3. CD11c , DX5 , NK1.1 ,
and CD3  cells were sorted by FACS Vantage III SE (Becton Dickinson),
and used as splenic DCs.
Priming of naive CD4  T cells. Naive CD4  T cells (5   105) from
line 94 mice or line 110 mice were cultured in 1 ml of cRPMI in a 48-well
plate with P13.9 fibroblast cells (1.25   105) stably expressing I-Ek, CD80,
and CD54 (37) that had been treated with 25  g/ml mitomycin C and
loaded with 0.001–10  M pPCC, or with splenic DCs (5   104) in the
presence of 0.001–10  M pPCC. In some experiments, naive CD4  T cells
were pretreated with U 0126 (MEK inhibitor), SB 203580 (p38 MAPK in-
hibitor), SP 600125 (JNK inhibitor), or DMSO (Sigma-Aldrich) at 37 C for
1 h. The final concentration of DMSO was 0.03%; this amount of DMSO
did not affect T cell growth or viability (unpublished data). When indicated
in figure legends, the following were added to the priming culture: neutral-
izing mAbs to IL-2, IL-4, IL-12, or IFN- ; blocking mAb to CD25 (10
 g/ml for all mAbs); or isotype-matched control mAbs.
Naive CD4  T cells (1   105) from Gata3f/fCD4-Cre mice or Gata3f/f
mice were stimulated with immobilized anti-CD3 (1  g/ml) and anti-
CD28 (3  g/ml) in the presence of recombinant human IL-2 (100 U/ml)
with or without anti–IL-4 (10  g/ml).
Quantitative RT-PCR. Stimulated cells were lysed in TRIzol (Invitro-
gen) and total RNA was isolated using RNeasy Midi Kit (QIAGEN) fol-
lowing the manufacturer’s instructions. One microgram of total RNA was
reverse-transcribed to cDNA using SuperScript II First-Strand Synthesis
System for RT-PCR (Invitrogen). Quantitative PCR was performed on a
7900HT sequence detection system (Applied Biosystems). The primer and
probe sets for detecting murine IL-2, IL-4, and IFN-  (FAM-MGB probe),
and TaqMan Ribosomal RNA Control Reagents for detecting the 18S ri-
bosomal RNA (VIC-MGB probe) were purchased from Applied Biosys-
tems. The sequences of primer and MGB probe for GATA-3 (34) and
c-Maf (38) are described elsewhere. The levels of mRNA for cytokines and
transcription factors were normalized to that of 18S ribosomal RNA.
Intracellular staining for IL-4/IFN- , phospho-STAT5, and phospho-
ERK. Primed T cells were harvested 72 h after stimulation, washed exten-
sively with HBSS, and cultured overnight in 2 ml of cRPMI containing
100 U/ml rhIL-2 in a 24-well plate. Cells were harvested, washed with
HBSS, and restimulated with immobilized anti-CD3 and anti-CD28 (3  g/
ml of each mAb) for 6 h. For the last 2 h, 2  M monensin (Calbiochem)
was added. Cells were harvested; fixed with 4% paraformaldehyde (PFA);
permeabilized with 0.5% Triton X-100 and 0.1% BSA in PBS; and stained
with PE–anti-IL-4, CyChrome–anti-CD4, and APC–anti-IFN- .
For phospho-STAT5 staining, 1   106 line 94 CD4  T cells that were
pretreated with U 0126 (3  M) or DMSO were stimulated with 2.5   105
P13.9 cells that were preloaded with 0.01 or 10  M pPCC in the presence
or absence of anti–IL-2 plus anti-CD25. Cells were harvested 24 and 48 h
after stimulation; fixed and permeabilized as described above; and then
stained with anti–phospho-STAT5 mAb followed by FITC-anti-CD25
(7D4), PE-anti–mouse Ig, and CyChrome–anti-CD4. CD25 expression
was detected on cell surface, not in cytoplasm, by a confocal microscope
(unpublished data).
For phospho-ERK staining, 1   106 line 94 CD4  T cells that were
pretreated with U 0126 (3  M) or DMSO were added to 2.5   105 P13.9
cells that were preloaded with 0.01 or 10  M pPCC in a 1.5-ml microcen-
trifuge tube, spun at 12,000 rpm for 10 s, and incubated at 37 C. Cells were
fixed with 4% PFA at various time points, permeabilized as described above,
and stained with anti–phospho-ERK mAb followed by PE-anti–mouse Ig
and CyChrome–anti-CD4.
Stained cells were acquired by a FACSCalibur (Becton Dickinson); the
data were analyzed using a CELLQuest software (Becton Dickinson) by
gating on CD4  T cells.
Confocal microscopic analysis for GATA-3 protein expression. U
0126 (3  M)– or DMSO-pretreated line 94 CD4  T cells (1   106) were
stimulated with P13.9 cells that were preloaded with 0.01 or 10  M pPCC.
Cells were harvested 20 h after stimulation, mounted on a coverslip, and
fixed with 4% PFA. Cells were permeabilized as described above, and
stained with anti–GATA-3 mAb followed by AlexaFluor 488–anti-CD4,
AlexaFluor 647 donkey–anti–mouse IgG, and DAPI. Stained cells were vi-
sualized with a Leica TCS-NT/SP confocal microscope with a 63  oil im-
mersion objective. 20 to 30 z sections separated by 0.2  m were acquired.
Reconstitutions of images were performed by using an Imaris software sys-
tem (BitPlane) and Photoshop software (Adobe Systems).
Western blot analysis for p56/p59lck. Line 94 CD4  T cells were stim-
ulated as described in “phospho-ERK staining.” After 20 and 60 min of in-
cubation, culture media was removed, and cells were treated with 40  l of
lysis buffer (1% NP-40, 10 mM Tris-HCl, 2 mM EDTA, 140 mM sodium
chloride, 1 mM sodium orthovanadate) freshly supplemented with protease
inhibitors (Complete Mini; Roche Applied Science) for 30 min on ice. Af-
ter removal of debris by centrifugation at 12,000 rpm for 15 min, 20  l of
3   SDS sample buffer (Cell Signaling Technology) was added to whole
cell lysates, and 20  l of aliquots were used for electrophoresis on an 8%
polyacrylamide gel (Invitrogen). Fractionated proteins were transferred onto
a nitrocellulose membrane (Bio-Rad Laboratories). Lck was detected with
rabbit anti-Lck polyclonal serum (BD Biosciences) followed by horseradish
peroxidase–labeled goat anti–rabbit IgG (Bio-Rad), and visualized with Su-
perSignal West Dura Extended Duration Substrate (Pierce Chemical Co.).
To confirm an equal loading, the probed membrane was stripped with Re-
store Western Blot Stripping Buffer (Pierce Chemical Co.) and reprobed
with anti-ZAP70 mAb (BD Biosciences) followed by horseradish peroxi-JEM VOL. 202, September 19, 2005 803
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dase–labeled goat anti–mouse IgG (Bio-Rad), and visualized with SuperSig-
nal West Pico Extended Duration Substrate (Pierce Chemical Co.).
Online supplemental material. Figs. S1 and S2 show the dot plot analy-
sis for CFSE versus IL-4 and the histograms of CFSE dilution correspond-
ing to Fig. 1, B and C, respectively. Fig. S3 shows the failure of IL-2 /  na-
ive line 94 CD4  T cells to produce early IL-4 in response to low
concentrations of pPCC. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20051304/DC1.
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